Empagliflozin and the risk of Gout: Analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study

被引：0
|
作者：
Koeneman, Lisette [1 ]
Tesfaye, Helen [2 ]
Paik, Julie M. [2 ]
Zabotka, Luke E. [2 ]
Htoo, Phyo T. [2 ]
Schmedt, Niklas [3 ]
Seman, Leo [4 ,5 ]
Wexler, Deborah J. [6 ,7 ]
Patorno, Elisabetta [2 ]
机构：
[1] Lilly Deutschland GmbH, Global Med Affairs, Bad Homburg, Germany
[2] Harvard Med Sch, Dept Med, Brigham & Womens Hosp, Div Pharmacoepidemiol, Boston, MA 02115 USA
[3] Boehringer Ingelheim Int GmbH, Dept Global Epidemio, Ingelheim, Germany
[4] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[5] Clin Dev & Med Affairs, Ridgefield, CT USA
[6] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA
[7] MGH Diabet Ctr, Div Endocrinol, Boston, MA USA
来源：
INNERE MEDIZIN | 2024年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P21-02
引用
收藏
页码：S145 / S145
页数：1
相关论文
共 50 条
  • [41] HEALTHCARE RESOURCE UTILIZATION IN PATIENTS TREATED WITH EMPAGLIFLOZIN IN EAST ASIA: RESULTS FROM EMPRISE STUDY
    Sheu, Wayne
    Seino, Yutaka
    Tan, Elise
    Yabe, Daisuke
    Ha, Kyoung Hwa
    Chung, Wook-Jin
    Taneda, Yusuke
    Lei, Wei-Yu
    Ustyugova, Anastasia
    Klement, Riho
    Deruaz-Luyet, Anouk
    Kyaw, Moe
    Kim, Dae Jung
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 1470 - 1470
  • [42] CARDIOVASCULAR EFFECTIVENESS OF EMPAGLIFLOZIN COMPARED TO DPP4I IN ROUTINE CARE IN EAST ASIA: RESULTS FROM THE EMPRISE STUDY
    Kim, Dae Jung
    Sheu, Wayne H-H
    Chung, Wook-Jin
    Yabe, Daisuke
    Ha, Kyoung Hwa
    Tan, Elise Chia-Hui
    Taneda, Yusuke
    Lei, Vanessa
    Saarelainen, Laura
    Deruaz-Luyet, Anouk
    Kyaw, Moe H.
    Seino, Yutaka
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 542 - 542
  • [43] Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study
    Engstrom, Arvid
    Soderling, Jonas
    Hviid, Anders
    Eliasson, Bjorn
    Gudbjornsdottir, Soffia
    Wintzell, Viktor
    Hveem, Kristian
    Jonasson, Christian
    Melbye, Mads
    Pasternak, Bjorn
    Ueda, Peter
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2024, 10 (05) : 432 - 443
  • [44] Comparative Cardiovascular and Renal Effectiveness of Empagliflozin and Dapagliflozin: Scandinavian Cohort Study
    Engstrom, Arvid
    Soderling, Jonas
    Hviid, Anders
    Eliasson, Bjorn
    Gudbjornsdottir, Soffia
    Wintzell, Viktor
    Hveem, Kristian
    Jonasson, Christian
    Melbye, Mads
    Pasternak, Bjorn
    Ueda, Peter
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 87 - 88
  • [45] Cardiovascular effectiveness of empagliflozin versus glucagon-like peptide-1 receptor agonists or liraglutide in the emprise study
    Htoo, Phyo
    Tesfaye, Helen
    Paik, Julie
    Wexler, Deborah
    Najafzadeh, Mehdi
    Glynn, Robert
    Deruaz-Luyet, Anouk
    Farsani, Soulmaz
    Koeneman, Lisette
    Schneeweiss, Sebastian
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 99 - 100
  • [46] Comparative effectiveness and safety of empagliflozin on cardiovascular mortality and morbidity in adults with type 2 diabetes
    Aronow, Wilbert S.
    Shamliyan, Tatyana A.
    ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (23)
  • [47] Cardiovascular Effectiveness of Empagliflozin vs. Glucagon-Like Peptide-1 Receptor Agonists or Liraglutide in the EMPRISE Study
    Htoo, Phyo T.
    Tesfaye, Helen
    Paik, Julie M.
    Wexler, Deborah J.
    Najafzadeh, Mehdi
    Glynn, Robert
    Deruaz-Luyet, Anouk
    Farsani, Soulmaz F. Fazeli
    Koeneman, Lisette
    Schneeweiss, Sebastian
    Patorno, Elisabetta
    DIABETES, 2022, 71
  • [48] Healthcare utilization and cost associated with empagliflozin in older adults with type 2 diabetes: Results from the EMPRISE study
    Htoo, Phyo Than T.
    Tesfaye, Helen
    Schneeweiss, Sebastian
    Wexler, Deborah
    Glynn, Robert J.
    Schmedt, Niklas
    Deruaz-Luyet, Anouk
    Koeneman, Lisette
    Paik, Julie M.
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 13 - 14
  • [49] Health Care Utilization and Cost Associated with Empagliflozin in Older Adults with Type 2 DiabetesResults from the EMPRISE study
    Htoo, Phyo T.
    Tesfaye, Helen
    Schneeweiss, Sebastian
    Wexler, Deborah J.
    Glynn, Robert
    Schmedt, Niklas
    Deruaz-Luyet, Anouk
    Koeneman, Lisette
    Paik, Julie M.
    Patorno, Elisabetta
    DIABETES, 2023, 72
  • [50] Healthcare resource utilisation after empagliflozin initiation in Europe: real-world evidence from the EMPRISE study
    Niskanen, L.
    Kyaw, M. H.
    Deruaz-Luyet, A.
    Ustyugova, A.
    Karlsdotter, K.
    Tuovinen, M.
    Casajust, P.
    Grip, E. Toresson
    Soreskog, E.
    Nystrom, T.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 229 - 229
12345